Begin main content

Find a Review (pCODR)

Updates on pCODR drug reviews underway are regularly posted to this page.

Completed reviews are posted on cadth.ca. They are searchable and freely available to anyone to use, download, or print for non-commercial and personal use, or private research and study, provided you do not modify them and appropriate credit is given to CADTH.

You can also find more general updates about pCODR on the pCODR Communication Updates page.

Brand Name Generic Name Tumour Type / Indication Review Status Last Updated
Adcetris Brentuximab vedotin Lymphoma
Systemic Anaplastic Large Cell Lymphoma
Notification to Implement Issued December 20, 2013
Arzerra Ofatumumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued February 23, 2015
Giotrif Afatinib Lung
Advanced Non Small Cell Lung Cancer
Notification to Implement Issued July 25, 2014
Xalkori Crizotinib Lung
First Line ALK Positive Advanced NSCLC
Notification to Implement Issued August 6, 2015
Kadcyla Trastuzumab emtansine Breast
Metastatic Breast Cancer
Notification to Implement Issued January 27, 2014
Zytiga Abiraterone acetate Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued November 6, 2013
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Resubmission Complete January 20, 2012
Treanda (in combination with rituximab) Bendamustine hydrochloride Leukemia
Chronic Lymphocytic Leukemia
Withdrawn September 26, 2014
Tykerb (in combination with Letrozole) Lapatinib Breast
Metastatic Breast Cancer
Notification to Implement Issued July 22, 2013
Revlimid Lenalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued November 6, 2013
Nexavar Sorafenib Endocrine
Metastatic Progressive Differentiated Thyroid Carcinoma (DTC)
Notification to Implement Issued September 29, 2015
Blincyto Blinatumomab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued April 18, 2016
Opdivo Nivolumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued August 15, 2016
Lynparza (Resubmission) Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued October 5, 2017
Jakavi Ruxolitinib Other
Polycythemia vera
Notification to Implement Issued March 18, 2016
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma (post-ASCT consolidation)
Withdrawn July 7, 2016
Vectibix Panitumumab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
Notification to Implement Issued April 16, 2018
Ninlaro Ixazomib Myeloma
Multiple Myeloma
Notification to Implement Issued July 17, 2017
Opdivo Nivolumab Head and Neck
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Notification to Implement Issued September 18, 2017
Onivyde Nanoliposomal Irinotecan Gastrointestinal
Metastatic Pancreatic Cancer
File-Closed Not Submitted December 2, 2016
Opdivo Nivolumab Gastrointestinal
Hepatocellular Carcinoma (HCC)
Notification to Implement Issued December 14, 2018
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma (previously untreated)
Notification to Implement Issued November 16, 2018
Darzalex Daratumumab Myeloma
Multiple Myeloma
Notification to Implement Issued December 16, 2016
Blincyto Blinatumomab Leukemia
Minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL)
Withdrawn October 16, 2018
Imbruvica Ibrutinib Leukemia
In combination with rituximab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL); In combination with obinutuzumab for previously untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL)
Not Filed July 17, 2019
Keytruda Pembrolizumab Lung
Non-Squamous NSCLC
Notification to Implement Issued June 17, 2019
Unituxin Dinutuximab Neurological
Neuroblastoma
Notification to Implement Issued April 10, 2019
Xalkori Crizotinib Lung
ROS1-positive advanced Non-Small Cell Lung Cancer
Notification to Implement Issued June 7, 2019
Bosulif (RFA) Bosutinib Leukemia
Chronic Myeloid Leukemia
Notification to Implement Issued August 2, 2019
TBD Rituximab Lymphoma & Leukemia
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
File-Closed Not Submitted April 29, 2019
TBD Gemtuzumab Ozogamicin Leukemia
Acute Myeloid Leukemia
Under Review October 29, 2019
Keytruda Pembrolizumab Genitourinary
Metastatic Urothelial Carcinoma (first line)
Notification to Implement Issued October 21, 2019
Cabometyx Cabozantinib Gastrointestinal
Hepatocellular Carcinoma
Under Review November 28, 2019
Kisqali Ribociclib Breast
Advanced or Metastatic Breast Cancer
Under Review November 18, 2019
Revlimid Lenalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued July 5, 2019
Lenvima Lenvatinib Gastrointestinal
Hepatocellular Carcinoma
Notification to Implement Issued August 13, 2019
Lonsurf Trifluridine-Tipiracil Gastrointestinal
Gastric Cancer
Under Review November 21, 2019
TBD Entrectinib Lung
ROS1-positive Non-Small Cell Lung Cancer
Pending December 4, 2019
Adcetris Brentuximab vedotin Lymphoma
Hodgkin Lymphoma
Notification to Implement Issued September 17, 2013
Avastin (with capecitabine) Bevacizumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued November 13, 2015
Votrient Pazopanib hydrochloride Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued Original Submission Complete September 17, 2013
Velcade Bortezomib Myeloma
Multiple Myeloma
Notification to Implement Issued April 11, 2013
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (Relapsed/ Refractory)
Notification to Implement Issued December 14, 2012
Bosulif Bosutinib Leukemia
Chronic Myeloid Leukemia
Notification to Implement Issued June 4, 2015
Perjeta Herceptin Combo Pack Pertuzumab Breast
Metastatic Breast Cancer
Notification to Implement Issued August 20, 2013
Stivarga (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued December 2, 2013
Halaven Eribulin Mesylate Breast
Metastatic Breast Cancer
Notification to Implement Issued August 20, 2012
Xtandi Enzalutamide Genitourinary
First Line Metastatic Castration-Resistant Prostate Cancer
Notification to Implement Issued July 31, 2015
Avastin Bevacizumab Gynecology
Cervical Cancer
Notification to Implement Issued April 8, 2015
Imbruvica Ibrutinib Lymphoma
Mantle Cell Lymphoma
Notification to Implement Issued August 4, 2016
Zydelig Idelalisib Lymphoma
Follicular Lymphoma
Notification to Implement Issued October 17, 2016
Afinitor Everolimus Endocrine
Neuroendocrine tumours of Gastrointestinal or Lung origin
Notification to Implement Issued December 16, 2016
Vectibix Panitumumab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued December 18, 2015
Kyprolis Carfilzomib Myeloma
Multiple Myeloma (relapsed)
Notification to Implement Issued April 17, 2017
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued November 17, 2017
Alecensaro Alectinib Lung
Locally advanced or metastatic non-small cell lung cancer (second line)
Notification to Implement Issued April 16, 2018
Ogivri Trastuzumab Breast / Gastrointestinal
Early Breast Cancer / Metastatic Breast Cancer / Metastatic Gastric Cancer Biosimilar
Withdrawn May 31, 2019
Erbitux Cetuximab Gastrointestinal
Left Sided Metastatic Colorectal Cancer
File-Closed Not Submitted April 26, 2018
Perjeta-Herceptin Combo Pack Pertuzumab-Trastuzumab Combo Pack Breast
Early Breast Cancer
Notification to Implement Issued December 14, 2018
Bavencio Avelumab Skin & Melanoma
metastatic Merkel Cell Carcinoma
Notification to Implement Issued April 6, 2018
Oncaspar Pegaspargase Leukemia
Adult Acute Lymphocytic Leukemia (ALL)
Not Filed June 17, 2019
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin & Melanoma
Melanoma Adjuvant Therapy
Notification to Implement Issued May 21, 2019
Ninlaro Ixazomib Myeloma
Multiple Myeloma (2nd-beyond)
Notification to Implement Issued July 22, 2019
Vizimpro Dacomitinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued June 17, 2019
Ibrance (with Faslodex) Palbociclib (with Fulvestrant) Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued May 21, 2019
TBD Darolutamide Genitourinary
Non-Metastatic Castration Resistant Prostate Cancer
Under Review November 12, 2019
Xospata Gilteritinib Leukemia
Acute Myeloid Leukemia (AML)
Under Review November 12, 2019
Idhifa Enasidenib Leukemia
Acute Myeloid Leukemia (AML)
Notification to Implement Issued November 15, 2019
Atriance Nelarabine Leukemia
Acute Lymphoblastic Leukemia
File-Closed Not Submitted October 29, 2019
Zytiga (Resubmission) Abiraterone Genitourinary
Prostate Cancer
Suspended November 5, 2019
Lutathera Lutetium Lu 177 dotatate Gastrointestinal
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Notification to Implement Issued August 19, 2019
Keytruda Pembrolizumab Skin & Melanoma
Melanoma Adjuvant Treatment
Notification to Implement Issued August 19, 2019
Adcetris Brentuximab Vedotin Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Under Review December 4, 2019
Lynparza Olaparib Gynecology
Ovarian Cancer
Final Recommendation Posted December 5, 2019
Afinitor Everolimus Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued September 18, 2012
Erbitux Cetuximab Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued January 27, 2014
Inlyta Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued March 22, 2013
Xtandi Enzalutamide Genitourinary
Metastatic Castration Resistant Prostate Cancer
Notification to Implement Issued August 8, 2013
Perjeta or Perjeta-Herceptin Combo Pack Pertuzumab Breast
Neoadjuvant Breast Cancer
Notification to Implement Issued September 29, 2015
Avastin Bevacizumab Gynecology
Ovarian Cancer
Notification to Implement Issued June 26, 2015
Sutent Sunitinib malate Gastrointestinal
Pancreatic neuroendocrine tumours
Notification to Implement Issued May 18, 2012
Treanda Bendamustine hydrochloride Leukemia
Chronic lymphocytic leukemia (First Line)
Notification to Implement Issued March 6, 2013
Votrient Pazopanib Hydrochloride Sarcoma
Soft Tissue Sarcoma (STS)
Notification to Implement Issued December 14, 2012
Stivarga (GIST) Regorafenib Other
Gastrointestinal Stromal Tumours
Notification to Implement Issued May 20, 2014
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (previously treated)
Notification to Implement Issued March 20, 2015
Opdivo Nivolumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued April 18, 2016
Opdivo Nivolumab Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued September 19, 2016
Zykadia Ceritinib Lung
Metastatic Non-Small Cell Lung Cancer
Notification to Implement Issued December 18, 2015
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued May 19, 2017
Keytruda Pembrolizumab Lymphoma
classical Hodgkin Lymphoma (cHL)
Notification to Implement Issued January 22, 2018
Rydapt Midostaurin Leukemia
Acute Myeloid Leukemia
Notification to Implement Issued January 11, 2018
Opdivo & Yervoy in combo Nivolumab & Ipilimumab in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 18, 2017
Gazyva Obinutuzumab Lymphoma
Follicular Lymphoma
Notification to Implement Issued June 19, 2017
Blincyto Blinatumomab Leukemia
Pediatric Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued September 8, 2017
Lonsurf Trifluridine and Tipiracil Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued July 23, 2018
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (first line)
Notification to Implement Issued August 13, 2018
Demylocan Decitabine Other
Myelodysplastic Syndromes
Not Filed May 29, 2019
TBD Trastuzumab Breast & Gastrointestinal
Breast and Gastric Cancer Biosimilar
File-Closed Not Submitted June 7, 2019
Truxima Rituximab Lymphoma & Leukemia
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia Biosimilar
File-Closed Not Submitted June 7, 2019
Imbruvica Ibrutinib Lymphoma
In combination with rituximab for Waldenstrom's Macroglobulinemia
Not Filed July 17, 2019
Folotyn Pralatrexate Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Notification to Implement Issued April 22, 2019
Ibrance Resubmission Palbociclib Breast
Advanced Breast Cancer
Notification to Implement Issued December 6, 2016
Zytiga Abiraterone Genitourinary
Prostate Cancer
Withdrawn May 3, 2019
Lenvima Lenvatinib Genitourinary
Renal Cell Carcinoma (RCC)
Notification to Implement Issued April 25, 2019
Darzalex Daratumumab Myeloma
Multiple Myeloma (newly diagnosed)
Notification to Implement Issued September 16, 2019
Rydapt Midostaurin Other
Systemic Mastocytosis
Under Review October 17, 2019
Stivarga Regorafenib Gastrointestinal
Unresectable Hepatocellular Carcinoma (HCC)
Notification to Implement Issued May 3, 2018
Kisqali Ribociclib Breast
Advanced or Metastatic Breast Cancer
Notification to Implement Issued May 3, 2018
Inlyta (RFA) Axitinib Genitourinary
Metastatic Renal Cell Carcinoma
Notification to Implement Issued June 30, 2017
Darzalex Daratumumab Multiple Myeloma
Myeloma
Under Review November 5, 2019
Verzenio Abemaciclib Breast
Advanced or metastatic breast cancer
Notification to Implement Issued July 22, 2019
Kadcyla Trastuzumab Emtansine Breast
Early Breast Cancer (EBC)
Under Review November 28, 2019
Tecentriq & Avastin Atezolizumab & Bevacizumab Lung
Non-Squamous Non-Small Cell Lung Cancer
Under Review December 4, 2019
Tecentriq Atezolizumab Lung
Small Cell Lung Cancer (SCLC)
Final Recommendation Posted December 5, 2019
Afinitor Everolimus Breast
Advanced Breast Cancer
Notification to Implement Issued April 11, 2013
Erivedge Vismodegib Skin and Melanoma
Advanced Basal Cell Carcinoma
Notification to Implement Issued January 27, 2014
Istodax Romidepsin Lymphoma
Peripheral T-Cell Lymphoma
Notification to Implement Issued June 26, 2015
Tafinlar & Mekinist in combo Dabrafenib & Trametinib in combo Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued September 29, 2015
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete October 22, 2012
Treanda Bendamustine hydrochloride Lymphoma
Non-Hodgkin lymphoma (NHL)
Notification to Implement Issued December 14, 2012
Stivarga Resubmission (CRC) Regorafenib Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued September 29, 2015
Zaltrap Aflibercept Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued September 23, 2014
Yervoy Ipilimumab Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued May 18, 2012
Sylvant Siltuximab Lymphoma
Multicentric Castleman's Disease (MCD)
Notification to Implement Issued July 8, 2015
Pomalyst Pomalidomide Myeloma
Multiple Myeloma
Notification to Implement Issued August 18, 2014
Zevalin Ibritumomab tiuxetan Lymphoma
Non-Hodgkin’s Lymphoma (NHL)
Not Filed June 17, 2019
TBD Bevacizumab Gastrointestinal / Lung
Metastatic Colorectal Cancer; Non-Small Cell Lung Cancer Biosimilar
File Closed June 17, 2019
Opdivo Nivolumab Skin & Melanoma
Melanoma Adjuvant Therapy
Notification to Implement Issued March 22, 2019
Venclexta in combo Rituximab Venetoclax Leukemia
Chronic Lymphocytic Leukemia (CLL)
Notification to Implement Issued June 17, 2019
Imfinzi Durvalumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued May 21, 2019
Opdivo in combination with Yervoy Nivolumab in combination with Ipilimumab Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued November 16, 2018
Erleada Apalutamide Genitourinary
Castrate Resistant Prostate Cancer
Notification to Implement Issued November 16, 2018
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia (with 17p deletion)
Withdrawn January 10, 2017
Caprelsa Vandetanib Endocrine
Medullary Thyroid Cancer
Notification to Implement Issued April 17, 2017
Tecentriq Atezolizumab Breast
Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Under Review October 21, 2019
Keytruda Pembrolizumab Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 1, 2015
Cotellic Cobimetinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued July 18, 2016
Imbruvica Ibrutinib Lymphoma
Waldenstrom's Macroglobulinemia
Notification to Implement Issued November 18, 2016
Imbruvica Ibrutinib Leukemia
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (previously untreated)
Notification to Implement Issued November 18, 2016
Lenvima Lenvatinib Endocrine
Differentiated Thyroid Cancer
Notification to Implement Issued October 5, 2016
Yondelis Trabectedin Sarcoma
Metastatic Liposarcoma or Leiomyosarcoma
Notification to Implement Issued August 22, 2016
Zykadia (Resubmission) Ceritinib Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued April 5, 2017
Kyprolis (with lenalidomide) Carfilzomib (with lenalidomide) Myeloma
Multiple Myeloma
Notification to Implement Issued November 11, 2016
Darzalex Daratumumab Myeloma
Multiple Myeloma (second-line or beyond)
Notification to Implement Issued October 24, 2017
Lartruvo Olaratumab Sarcoma
Advanced Soft Tissue Sarcoma (STS)
Notification to Implement Issued May 3, 2018
Opdivo Nivolumab Lymphoma
classical Hodgkin Lymphoma after failure of ASCT
Notification to Implement Issued May 22, 2018
Keytruda Pembrolizumab Genitourinary
Metastatic Urothelial Carcinoma
Notification to Implement Issued March 19, 2018
Tecentriq Atezolizumab Lung
Non-Small Cell Lung Cancer
Notification to Implement Issued July 6, 2018
Keytruda Pembrolizumab Lung
Squamous NSCLC
Under Review November 19, 2019
Kisqali Ribociclib with Fulvestrant Breast
Advanced or Metastatic Breast Cancer
Under Review November 18, 2019
Lorbrena Lorlatinib Lung
Non-Small Cell Lung Cancer (NSCLC)
Open for Feedback on Recommendation December 5, 2019
Vitrakvi Larotrectinib Other
Neurotrophic Tyrosine Receptor Kinase (NTRK) Locally Advanced or Metastatic Solid Tumours
Notification to Implement Issued November 15, 2019
Abraxane Nab-paclitaxel Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued October 8, 2014
Trisenox Arsenic Trioxide Leukemia
Acute Promyelocytic Leukemia
Notification to Implement Issued February 18, 2014
Tafinlar Dabrafenib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued December 20, 2013
Jakavi Ruxolitinib Other
Myelofibrosis
Notification to Implement Issued January 30, 2013
Xalkori Crizotinib Lung
Advanced Non-Small Cell Lung Cancer
Notification to Implement Issued Original Submission Complete June 17, 2013
Mekinist Trametinib Skin and Melanoma
Metastatic Melanoma
Notification to Implement Issued November 6, 2013
Gazyva Obinutuzumab Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued June 26, 2015
Alimta Pemetrexed Lung
Advanced Non-Squamous Non Small Cell Lung Cancer
Notification to Implement Issued December 5, 2013
Proleukin Aldesleukin (IL-2) Skin and Melanoma
In-transit Melanoma
Notification to Implement Issued July 31, 2015
Zelboraf Vemurafenib Skin and Melanoma
Advanced Melanoma
Notification to Implement Issued August 1, 2012
Yervoy Ipilimumab Skin and Melanoma
First Line Advanced Melanoma
Notification to Implement Issued January 15, 2015
Revlimid Lenalidomide Myeloma
Multiple Myeloma (newly diagnosed)
Notification to Implement Issued December 18, 2015
Ibrance Palbociclib Breast
Advanced Breast Cancer
Suspended July 25, 2016
Cyramza Ramucirumab Lung
Non-Small Cell Lung Cancer
File-Closed Not Submitted May 20, 2016
Blincyto (Resubmission) Blinatumomab Leukemia
Adult Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued September 18, 2017
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Carcinoma (First Line)
Notification to Implement Issued September 8, 2017
Avastin Bevacizumab Lung
Malignant Pleural Mesothelioma
Withdrawn April 11, 2017
Avastin Bevacizumab Gynecology
Platinum-Resistant Ovarian Cancer
Notification to Implement Issued August 15, 2016
Keytruda Pembrolizumab Lung
Non-Small Cell Lung Cancer (Second Line or Beyond)
Notification to Implement Issued November 18, 2016
Lynparza Olaparib Gynecology
Ovarian Cancer
Notification to Implement Issued October 17, 2016
Alecensaro Alectinib Lung
Non-Small Cell Lung Cancer (with CNS metastases)
Notification to Implement Issued May 19, 2017
Rituxan Rituximab Leukemia
Acute Lymphoblastic Leukemia
Notification to Implement Issued September 18, 2017
Xtandi Enzalutamide Genitourinary
Non-metastatic castration-resistant prostate cancer
Notification to Implement Issued April 10, 2019
Blincyto Blinatumomab Leukemia
Philadelphia chromosome positive (Ph+) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL)
Notification to Implement Issued April 22, 2019
Cabometyx Cabozantinib Genitourinary
Renal Cell Carcinoma
Notification to Implement Issued March 7, 2019
Lonsurf Trifluridine and Tipiracil Gastrointestinal
Metastatic Colorectal Cancer
Notification to Implement Issued September 16, 2019
Libtayo Cemiplimab Skin & Melanoma
Cutaneous Squamous Cell Carcinoma
Under Review October 21, 2019
TBD Entrectinib Other
Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion-Positive Solid Tumours
Under Review October 23, 2019
Cyramza Ramucirumab Gastrointestinal
Metastatic Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma
Notification to Implement Issued November 13, 2015
Iclusig Ponatinib Leukemia
Chronic Myeloid Leukemia/ Acute Lymphoblastic Leukemia
Notification to Implement Issued October 20, 2015
Zydelig Idelalisib Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued September 2, 2015
Erleada Apalutamide Genitourinary
Metastatic Castration-Sensitive Prostate Cancer
Under Review October 31, 2019
Keytruda Pembrolizumab Genitourinary
Renal Cell Carcinoma
Under Review October 31, 2019
Pomalyst Pomalidomide Myeloma
Multiple Myeloma (second-line or beyond)
Notification to Implement Issued October 3, 2019
Tagrisso Osimertinib Lung
Non-Small Cell Lung Cancer (first line)
Notification to Implement Issued January 21, 2019
Faslodex Fulvestrant Breast
Locally Advanced or Metastatic Breast Cancer
Notification to Implement Issued February 16, 2018
Adcetris Brentuximab Vedotin Lymphoma
Hodgkin’s Lymphoma at high risk of relapse or progression post-ASCT
Notification to Implement Issued March 8, 2018
Venclexta Venetoclax Leukemia
Chronic Lymphocytic Leukemia
Notification to Implement Issued March 19, 2018
Onivyde Irinotecan Liposome Gastrointestinal
Metastatic Pancreatic Cancer
Notification to Implement Issued January 22, 2018
TBD Cabozantinib Genitourinary
Renal Cell Carcinoma (RCC)
Withdrawn January 25, 2018
Besponsa Inotuzumab Ozogamicin Leukemia
Acute Lymphoblastic Leukemia (ALL)
Notification to Implement Issued July 23, 2018
Beleodaq Belinostat Lymphoma
Peripheral T-Cell Lymphoma (PTCL)
Withdrawn October 24, 2018
Mvasi Bevacizumab Gastrointestinal / Lung
Metastatic Colorectal Cancer / Non-Small Cell Lung Cancer Biosimilar
Final Biosimilar Dossier Issued January 14, 2019
Adcetris (Resubmission) Brentuximab Vedotin Lymphoma
Hodgkin Lymphoma
Notification to Implement Issued March 22, 2019
Alunbrig Brigatinib Lung
Non-Small Cell Lung Cancer (NSCLC)
Notification to Implement Issued August 19, 2019
Nerlynx Neratinib Breast
Hormone Receptor-Positive Breast Cancer
Final Recommendation Posted December 5, 2019